CA Patent

CA3249723A1 — Formulation for treating urinary system disorders

Assigned to Watershed Medical Inc · Expires 2023-10-26 · 3y expired

What this patent protects

Embodiments include intravesical therapies for the treatment of ailments such as urinary system disorders. A controlled release drug delivery system is administered into the urinary bladder of a patient. Controlled release particles in the formulation can include a pharmacologica…

USPTO Abstract

Embodiments include intravesical therapies for the treatment of ailments such as urinary system disorders. A controlled release drug delivery system is administered into the urinary bladder of a patient. Controlled release particles in the formulation can include a pharmacologically active agent and an excipient (i.e., controlled release carrier). Particle buoyancy in urine and size ensure that the formulation is retained within a patient's bladder and releases the active agent into the bladder through the duration of an extended drug delivery time period. Methods of treating urinary system disorders by intravesicular administration of the particle formulation are also described, and include methods of treating urinary system infections, bladder cancer, incontinence, and other urinary system disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA3249723A1
Jurisdiction
CA
Classification
—
Expires
2023-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Watershed Medical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.